Toronto researcher's discovery points to a new treatment avenue for acute myeloid leukemia

Toronto, July 6, 2009-- Dr. John Dick, Senior Scientist at the Ontario Cancer Institute, the research arm of Princess Margaret Hospital, co-led a multinational team that has developed the first leukemia therapy that targets a protein, CD123, on the surface of cancer stem cells that drive acute mye...

Study IDs benefit of donor SCT for adults with acute myeloid leukemia

BOSTON--A stem cell transplant (SCT) from a compatible donor early in the course of disease is the best approach for the majority of young and middle-aged adult patients with acute myeloid leukemia (AML), according to a new analysis of two dozen clinical studies. The findings of the study, publ...

Donor Stem-Cell Transplant Best For Acute Myeloid Leukemia

People in all risk groups, but especially those with poor and intermediate risk of survival, benefit most, researchers say TUESDAY, June 9 (HealthDay News) -- For most patients with acute myeloid leukemia (AML) who come out of remission, donor stem cells appear to offer the best shot a...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO

-- Conference Call Scheduled for Monday June 1 at 1:00 PM ET to Discuss ASCO Data Presentations -- SOUTH SAN FRANCISCO, Calif., May 26 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical company focused on the development and commercialization of ne...

Enhancing the effects of the drug used to treat chronic myeloid leukemia

Individuals with chronic myeloid leukemia (CML) are first treated with a drug known as imatinib mesylate. Although very effective, as the disease progresses it often becomes resistant to the drug. However, a team of researchers, at the University of Leicester, United Kingdom, and Thomas Jefferson ...

Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse

The study is supported by The Leukemia & Lymphoma Society(R) PRINCETON, N.J., March 10 /PRNewswire/ -- Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Lip...

Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia

CAMBRIDGE, Mass., Dec. 17 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR ) announced today that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company's oxygen therapeutic Hem...

Genetic Changes May Dictate Course of Acute Myeloid Leukemia

Findings could help determine which therapies will benefit certain patients WEDNESDAY, April 30 (HealthDay News) -- Breakthroughs in understanding the extremely fine genetic underpinnings of acute myeloid leukemia may allow doctors to quickly decide which existing therapies will most b...

Kidney cancer drug attacks a major type of acute myeloid leukemia

HOUSTON - A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia (AML), the most common and lethal form of adult leukemia, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan. 29 edition...

New drug candidate knocks out resistant form of chronic myeloid leukemia

PORTLAND, Ore. Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML). This drug candidate could build on the legacy of Gleevec, which has been the ...

Myeloid in Medical Technology

Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)

Response Observed Across All Subtypes of AML, Including Those with Poorest Prognoses SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Eisai Corporation of North America today announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute m...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

--Complete Remissions Achieved with Voreloxin in Poor Risk Frontline Elderly AML and in Combination with Cytarabine in Relapsed/Refractory AML- --Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML-- SAN FRANCISCO , Dec. 7 /...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

-- Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical company focused on the development and comme...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

- Voreloxin Demonstrates Promising Clinical Activity in Patients with Difficult-to-Treat Cancers - SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) presented data from three clinical trials of the company's lead ...

Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

Data from Phase 1 Single Agent and Phase 1b Combination Clinical Trials Demonstrate Voreloxin's Anti-Leukemic Activity SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) presented data Saturday from two clinical trials of t...

Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) will present data from ongoing clinical trials of voreloxin (formerly SNS-595) at two major upcoming oncology conferences. Updated interim data from Sunesis' ongoing Phase 2 clinical ...

Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., May 21 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today announced the initiation of the REVEAL-1 (Response Evaluation of Voreloxin in Elderly AML) Phase 2 clinical trial of voreloxin (also known as SNS-595), the company's lead anti-can...

Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)

Unique monoclonal antibody successfully targets human leukemic stem cells ATLANTA, Dec. 10 /PRNewswire/ -- CSL Limited, Australia's leading biopharmaceutical company, has today presented data at the American Society of Hematology (ASH) 49th annual meeting, which demonstrate the promising pre-cl...

CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia

BRANFORD, Conn., Aug. 28 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase I/II clinical trial evaluating belinostat (PXD101), a histone deacetylase (HDAC) inhibitor, i...

Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice

NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Xenomics, Inc. (the "Company") (Pink Sheets: XNOM; FWB: XE7) a developer of next-generation medical DNA diagnostic technologies, announced today that its first diagnostic test developed for stratification of patients with Acute Myeloid Leukemia (AML) ...

Myeloid in Medical Products

NeutroSpec™

Description:...rly the "function" of the appendix rather than just the anatomy - resulting in a reliable diagnosis. NeutroSpec attaches to the white blood cells (and myeloid precursors) at the site of the infected appendix, "lighting up" the infection at its source. In the pivotal trial, NeutroSpec was found to be 96 perce...
Company:Tyco Healthcare Group LP

Myeloid in Medical Definition

Hematopathology

... • LPD • Myeloma ( Multiple myeloma , Extramedullary plasmacytoma ) myeloid : myeloid leukemia ( AML , CML ) • MPD Ph- ( Essential thrombocytosis , Polycyth...

Pathology

... • LPD • Myeloma ( Multiple myeloma , Extramedullary plasmacytoma ) myeloid : myeloid leukemia ( AML , CML ) • MPD Ph- ( Essential thrombocytosis , Polycyth...

Personalized medicine

...aking them eligible. Herceptin sales have grown from $30.5 million in 1998, its year of introduction, to $764 million in 2005. Gleevec treats chronic myeloid leukaemia (CML) arrived in 2004 and it is known as a targeted cancer drug. In addition because of new molecular testing for c-kit, tumors such as GIS...

Myeloid in Medical Dictionary

Myeloproliferative Disorders

...are related to, and may evolve into, myelodysplastic syndrome and acute myeloid leukemia, although the myeloproliferative diseases on the whole... M...rights reserved. ... Myeloproliferative disorders include chronic myeloid leukemia, polycythemia vera, ... © 2004-2008, The Myeloproliferative D...

Leukemia

...on on leukemia including lymphocytic leukemia , myeloid leukemia , hairy cell leukemia , childhood le..... Hutchinson Center research related to Acute myeloid Leukemia (also known as Acute Myelogenous Leukemia ), AML information, and Acute myeloid Leukemia risk. ... ...

Cml

...mia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow... CML Innovative Technologies provides its ...Food and Drug Administration approved today for the treatment of chronic myeloid leukemia ( CML ), a cancer of ... Fighting leukemia, lymphoma, Hodgk...

Acute myelogenous leukemia

... Acute myeloid leukemia (AML), also known as acute myelogenous leukemia , is a cancer of the myeloid line of blood cells, characterized by the rapid ...us leukemia (AML, also sometimes called acute myeloid leukemia or acute nonlymphocytic leukemia ) i...

Myeloid in Biological News

La Jolla Institute discovers novel tumor suppressor

...blood cells by the bone marrow and include chronic myeloid leukemia. Lymphoma and leukemia are cancers of th...f blood stem cells, to promote the development of myeloid cells. Myeloproliferative diseases develop when myeloid cells -- which make certain types of white blood c...

Comprehensive look at rare leukemia finds relatively few genetic changes launch disease

... The most comprehensive analysis yet of the genome of childhood acute myeloid leukemia (AML) found only a few mistakes in the genetic blueprint, suggesti...tered in hematopoietic stem cells, multi-potential progenitors or committed myeloid progenitors to convert them from a normal cell to AML," the authors noted, ...

Stem cell protein offers a new cancer target

...ansform cells to a cancerous state, and that it is abundant in a variety of advanced human cancers, particularly liver cancer, ovarian cancer, chronic myeloid leukemia, germ cell tumors and Wilm's tumor (a childhood kidney cancer). They believe that overall, LIN28 and a related protein, LIN28B, may be involv...

Study finds blood cells can be reprogrammed to act as embryonic stem cells

...tiated cells expressed genes for all three embryonic germ layers (the tissues from which all other tissue types in the body develop) and also produced myeloid and granulocyte colonies (types of white blood cells). The group confirmed that the reprogrammed cells had acquired ES cell characteristics by inje...

Scientists identify key gene that protects against leukemia

...he scientists noted a progressive expansion of the myeloid lineage, which constitutes a type of mature white ...erating and the rate of differentiation toward the myeloid lineage that ultimately results in leukemia. The s...cient mice consistently displayed higher levels of myeloid lineage than the control group, indicating constan...

A miR boost enables acute leukemia cells to mature

... COLUMBUS, Ohio A new study by Ohio State University cancer researchers shows that boosting the level of a molecule called miR-29b in acute myeloid leukemia (AML) cells can reverse gene changes that trap the cells in an immature, fast growing state of development. The study discovered how the ...

CSHL team develops mouse models of leukemia that predict response to chemotherapy

...g Harbor Laboratory (CSHL), have come closer to achieving these critical goals for human cancer therapy by developing new mouse models for human acute myeloid leukemia (AML), an aggressive and devastating cancer of white blood cells. As Lowe and colleagues report in the April 1st issue of the journal Ge...

Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine

...microbiology & immunology $1,069,157 Roles of microRNAs in hepatic stem cell differentiation; transcriptional control of cancer stem cells in acute myeloid leukemia. Eric Bouhassira, Ph.D., the Ingeborg and Ira Leon Rennert Professor of Stem Cell Biology and Regenerative Medicine $971,489 Characteriz...

In just 5 years, gene discovery to clinical trial of potential treatment

...ies. The two and one-half year phase 2 clinical trial, which began in 2007, is evaluating the FTI drug lonafarnib. In clinical studies in people with myeloid leukemia, neurofibromatosis and other conditions, FTIs' side effects were minimal. The 2003 discovery of the HGPS gene, named lamin A (LMNA), laid ...

The MDS foundation supports vidaza's recommendation for European approval

...those with high-risk MDS, chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). The CHMP positive opinion was based upon data from the A...A-001 trial also showed that, VIDAZA delays the progression of MDS to acute myeloid leukemia (AML). Roughly 30 percent of patient diagnosed with MDS will prog...

Myeloid in Biological Technology

Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)

- Study also points to potential of pre-treatment R2 levels as a possible predictor of clinical activity - TORONTO, July 2 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the re...

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia

- Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Gleevec as standard of care - Study did not meet primary endpoint at 1 year, yet shows faster time to molecular responses with...

Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia

EXPANDED CLINICAL PROGRAM SUPPORTED BY PROMISING RESULTS FROM COMPLETED TRIAL TORONTO, Aug. 29 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceu...

Sunesis Reports Financial Results for the Second Quarter 2009

...f patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer. About Acute myeloid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone...

Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates

... of drugs under development". "We recently announced excellent survival data for our lead development product elacytarabine in late-stage acute myeloid leukaemia. The new funds will be invested in a Phase II/III registration trial for elacytarabine in this patient population. Another key trial for us ...

Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia

...abine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). In the trial, elacytarabine showe...fficult-to-treat patient group is late-stage acute myeloid leukaemia (AML) patients who have failed two previ... established anti-cancer agent often used in acute myeloid leukaemia. Unlike cytarabine, uptake of elacytarab...

Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress

...cal outcomes. The company pipeline includes: CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-571 (a liposomal for...

Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting

...e effect of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the Am... -- Resistance to imatinib therapy (Gleevec(R)) in patients with chronic myeloid leukemia (CML): Scientists from Quest Diagnostics, University of Texas M...

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting

...00 p.m., Level 3, W340A Acute myeloid Leukemia Phase 1/2 Study of Idarubicin, High Dose Ara-C and Sorafenib in Patients with Acute myeloid Leukemia Younger than 65 Years Farhad Ravandi, M.D., The Univ...

Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

...r vaginal carriage of Group B Streptococcus Xpert(R) BCR-ABL Monitor Monitoring test for patients with Chronic myeloid Leukaemia (CML) Congress attendees can also look forward to a wide variety of insightful presentations, based ...

Myeloid in Biological Products

Mouse Anti-Human Myeloid Marker Monoclonal Antibody, Unconjugated, Clone BM-1 from Santa Cruz Biotechnology, Inc.

Description: Myeloid Marker (BM-1)...
Company:Santa Cruz Biotechnology, Inc.

Mouse Oncostatin M from StemCell Technologies, Inc.

Description:... density lipoprotein receptor expression on hepatoma cells. Mouse OSM was recently cloned and identified as an immediate early gene induced in various myeloid and lymphoid cell lines by a subset of cytokines including IL-2, IL-3, GM-CSF and EPO. For Research Purposes only. Not to be administered to humans....
Company:StemCell Technologies, Inc.

Myeloid in Biological Dictionary

Aneuploidy

...brary :: Aneuploidy :: The selective use of rapid aneuploidy screening in prenatal diagnosis. Continuous growth and differentiation of human myeloid ... ...